Contrastingly, subjects using sulfonylurea or insulin or who had obesity at baseline were significantly less likely to continue treatment with dulaglutide (OR [95% CI]: 0.41 (0.20, 0.81), 0.26 (0.11, 0.58), and 0.33 (0.11, 0.91), respectively; with all p < 0.05). The gene discussed is INS; the disease is obesity disorder.